8-K: Co-Diagnostics Secures $3.8M in Direct Offering

Co-Diagnostics, Inc. has entered into a securities purchase agreement with institutional investors for a registered direct offering of 9.6 million common shares, expected to generate approximately $3.8 million in gross proceeds.

Summary

• Co-Diagnostics, Inc. (CODX) entered into a Securities Purchase Agreement on September 17, 2025, with two institutional investors for a registered direct offering.
• The company will issue and sell 9,619,000 shares of common stock at an offering price of $0.40 per share.
• The aggregate gross proceeds are estimated to be approximately $3.8 million before deducting fees and expenses.
• Maxim Group LLC is acting as the exclusive placement agent, receiving a 7.0% cash fee of gross proceeds and reimbursement for out-of-pocket expenses up to $50,000.
• The offering is expected to close on September 18, 2025.
• Proceeds are intended for working capital and general corporate purposes.
• Investors receive participation rights for up to 30% each in subsequent financings within 12 months, subject to beneficial ownership limitations (4.99% or 9.99% at election) and excluding certain exempt issuances like at-the-market offerings.
• The company has agreed to a 30-day restriction on issuing common stock or common stock equivalents following the closing.

Sentiment

Score: 4

Explanation: The capital raise provides essential liquidity for working capital, which is a positive. However, the significant dilution at a very low share price, coupled with the ongoing Nasdaq minimum bid price compliance issue, indicates underlying challenges and a distressed valuation. The participation rights for future financings could also be seen as a mixed signal, suggesting potential further dilution.

Positives

• Secured approximately $3.8 million in gross proceeds, providing crucial working capital and funds for general corporate purposes.
• The offering is a registered direct offering, indicating a structured approach to capital raising.
• The expected closing date is very soon (September 18, 2025), ensuring timely access to funds.

Negatives

• Significant dilution for existing shareholders due to the issuance of 9,619,000 new shares at a low price of $0.40 per share.
• The offering price of $0.40 per share is substantially below the company's historical trading levels, reflecting a depressed valuation.
• The company received a notice on July 11, 2025, regarding non-compliance with Nasdaq's minimum bid price requirement, indicating potential delisting risk.
• Placement agent fees of 7.0% of gross proceeds and up to $50,000 in expenses will reduce net proceeds.
• The 30-day lock-up on further equity sales might limit immediate financing flexibility, though it provides some stability.

Risks

• Dilution Risk: The issuance of 9,619,000 shares at $0.40 will significantly dilute the ownership stake of existing shareholders.
• Nasdaq Delisting Risk: The company received a notice on July 11, 2025, regarding non-compliance with Nasdaq's minimum bid price requirement, which could lead to delisting if not resolved.
• Market Price Volatility: The low offering price and potential for further equity raises could exert downward pressure on the common stock's market price.
• Future Financing Terms: While investors have participation rights, future financings could still occur at unfavorable terms if market conditions or company performance deteriorates.
• Operational Risks: The use of proceeds for 'working capital and general corporate purposes' is broad and does not specify particular growth initiatives or risk mitigation strategies.

Future Outlook

The offering is expected to close on September 18, 2025. The company intends to use the proceeds for working capital and general corporate purposes. Investors in this offering will receive participation rights for up to 30% each in any subsequent financing within 12 months, subject to certain beneficial ownership limitations and exclusions.

Management Comments

• Management intends to use the proceeds from the offering for working capital and general corporate purposes.

Industry Context

The molecular diagnostics industry, while critical for healthcare, often requires significant capital for research, development, and commercialization. Companies in this sector frequently raise capital through equity offerings to fund operations, especially when facing market challenges or pursuing new product development. This offering provides Co-Diagnostics with necessary liquidity in a competitive and capital-intensive industry.

Stakeholder Impact

• Shareholders: Existing shareholders will experience significant dilution due to the issuance of new shares at a low price.
• Company: The company gains crucial working capital to fund operations and general corporate purposes, potentially improving its financial stability.
• Investors (new): The institutional investors acquire a substantial stake at a discounted price and gain participation rights in future financings.

Next Steps

• Closing of the registered direct offering on or about September 18, 2025.
• Use of proceeds for working capital and general corporate purposes.
• Company to maintain Nasdaq listing and apply to list the newly issued shares.

Key Dates

Recommendation

While the capital raise provides much-needed liquidity for Co-Diagnostics, the significant dilution at a deeply discounted share price of $0.40, coupled with the ongoing Nasdaq minimum bid price compliance issue, signals considerable financial distress and operational challenges. Existing shareholders face immediate dilution and potential further downside risk from the low valuation and the need for future capital. For new investors, the low entry price and participation rights might be attractive, but the underlying business challenges and delisting risk warrant caution. A 'hold' recommendation is appropriate for existing investors to monitor the effective use of capital and progress on Nasdaq compliance, while new investors should approach with extreme caution given the high risk profile.

Keywords

Co-Diagnostics, CODX, Registered Direct Offering, Equity Financing, Common Stock, Institutional Investors, Working Capital, Nasdaq, Dilution, Molecular Diagnostics